Navigation Links
AIUM and ACEP publish guidelines for performing emergency trauma ultrasound -- the FAST exam
Date:12/7/2007

The American Institute of Ultrasound in Medicine (AIUM) and the American College of Emergency Physicians (ACEP) officially announced today that they will publish jointly the Guideline for the Performance of the FAST (Focused Assessment with Sonography in Trauma) Examination.

The FAST examination is a proven and useful procedure for the evaluation of the injured patient immediately during resuscitation to detect large abnormal fluid collections or other collections that need immediate treatment. Prior to its use, more invasive procedures, including surgery, were required to evaluate trauma patients.

With the growing use of the FAST examination to evaluate trauma patients in hospital emergency rooms, pre-hospital situations, military locations, and disaster areas, the AIUM and ACEP joined forces to create guidelines to provide assistance to emergency medical practitioners and to promote high-quality ultrasound examinations.

Created with expert input from both traditional and emergency physician ultrasound experts, the FAST guideline includes indications for performing the examination, qualifications and responsibilities of the performing physician, specifications for individual examinations, documentation requirements, equipment specifications, quality control, and safety standards.

The FAST examination is now taught to more than 95% of emergency medicine residents and included in Advanced Trauma Life Support, a training program for doctors in the management of acute trauma cases. The FAST examination is widely accepted as the standard of care for the initial assessment and treatment in trauma centers.

Vivek Tayal, MD, FACEP, Chair of the ACEP Section of Emergency Ultrasound and member of the AIUM, commented that the joint Guideline for the Performance of the FAST Examination will help the FAST examination gain further national and international prominence.

The FAST Guideline reinforces ACEPs ultrasound im
'/>"/>

Contact: Stacey Batchellor
sbatchellor@aium.org
301-498-4100
American Institute of Ultrasound in Medicine
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Two studies published in the Lancet
2. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
3. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
4. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
5. New report on mobile phone research published
6. Experts Publish New Lung Disease Guidelines
7. American College of Physicians publishes The Fenway Guide to LGBT Health
8. New study questions the validity of publishing hospital mortality rates
9. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
10. Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
11. Clinical Study Published Showing Benefits of Glue Used in Facelift Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6GeoVax Labs Requests pre IND Meeting With FDA 14181 1GeoVax Labs Requests pre IND Meeting With FDA 14181 2GeoVax Labs Requests pre IND Meeting With FDA 14181 3Dalton Pharma Services Adds Formulation Development Services 57793 1Dalton Pharma Services Adds Formulation Development Services 57793 2Atlantic Partners with Childrens Hospital of Philadelphia to Create an Interactive 26 Educational Waiting Room 57788 1Atlantic Partners with Childrens Hospital of Philadelphia to Create an Interactive 26 Educational Waiting Room 57788 2